Usefulness of C-Reactive Protein and Interleukin-6 as Predictors of Outcomes in Patients With Chronic Obstructive Pulmonary Disease Receiving Pravastatin

American Journal of Cardiology

Volumn 101, Issue 4, 2008, Pages 530-535

  Lee, Tsung Ming ^a   Lin, Mei Shu ^b   Chang, Nen Chung ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; EXERCISE; FEMALE; FOLLOW UP; HEART RATE; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; STATISTICAL SIGNIFICANCE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; DOUBLE-BLIND METHOD; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; MALE; PRAVASTATIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 38849125493     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.09.102     Document Type: Article

References (14)

1. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., and Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45 (2005) 1644-1648
2. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
3. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases?. The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
4. Yende S., Waterer G.W., Tolley E.A., Newman A.B., Bauer D.C., Taaffe D.R., Jensen R., Crapo R., Rubin S., Nevitt M., et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 61 (2006) 10-16
5. Broekhuizen R., Wouters E.F., Creutzberg E.C., and Schols A.M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61 (2006) 17-22
6. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S., and GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 163 (2001) 1256-1276
7. Wilson R.C., and Jones P.W. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnea during exercise. Clin Sci 76 (1989) 277-282
8. Baumann H., and Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 7 (1990) 147-159
9. Allain C.C., Poon L.S., Chan C.G., Richmond W., and Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem 20 (1974) 470-475
10. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., et al., Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
11. de Torres J.P., Cordoba-Lanus E., López-Aguilar C., Muros de Fuentes M., Montejo de Garcini A., Aguirre-Jaime A., Celli B.R., and Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 27 (2006) 902-907
12. Kuo H.K., Yen C.J., Chen J.H., Yu Y.H., and Bean J.F. Association of cardiorespiratory fitness and levels of C-reactive protein: data from the National Health and Nutrition Examination Survey 1999-2002. Int J Cardiol 114 (2007) 28-33
13. Ray K.K., Cannon C.P., Cairns R., Morrow D.A., Rifai N., Kirtane A.J., McCabe C.H., Skene A.M., Gibson C.M., Ridker P.M., Braunwald E., and PROVE IT-TIMI 22 Investigators. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1417-1424
14. Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., and Taylor A.J. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J 145 (2003) e8